Justin Klee (L) and Joshua Cohen, Amylyx co-CEOs (Cody O'Loughlin/The New York Times; courtesy Amylyx)

Ad­vo­cates, ex­perts cry foul over Amy­lyx's new ALS drug, cit­ing is­sues with price, PhI­II com­mit­ment

Not 24 hours af­ter earn­ing the first ALS drug ap­proval in five years, Amy­lyx Phar­ma­ceu­ti­cals’ Re­lyvrio is al­ready draw­ing scruti­ny. And it’s com­ing from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.